866-997-4948(US-Canada Toll Free)

Cathepsin S (CTSS or EC 3.4.22.27)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 34 Pages

Cathepsin S (CTSS or EC 3.4.22.27)-Pipeline Review, H2 2017

Summary

Cathepsin S (CTSS or EC 3.4.22.27) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report Cathepsin S (CTSS or EC 3.4.22.27)-Pipeline Review, H2 2017, outlays comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cathepsin S (CTSS or EC 3.4.22.27)-Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. Cathepsin S has a role in itch and pain, or nociception. The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family. Cathepsin S has a physiological role outside the lysosome. Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides, proinflammatory cytokines and neutrophils. The molecules developed by companies in Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 1, 6 and 1 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Oncology, Infectious Disease, Metabolic Disorders and Musculoskeletal Disorders which include indications Neuropathic Pain, Rheumatoid Arthritis, Alzheimer's Disease, Autoimmune Disorders, Cancer Pain, Celiac Disease, Chagas Disease (American Trypanosomiasis), Colorectal Cancer, Crohn's Disease (Regional Enteritis), Diabetic Retinopathy, Liver Fibrosis, Lupus Nephritis, Osteoarthritis, Pancreatic Cancer, Primary Biliary Cirrhosis, Sicca Syndrome (Sjogren) and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)
- The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cathepsin S (CTSS or EC 3.4.22.27)-Overview 6
Cathepsin S (CTSS or EC 3.4.22.27)-Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Cathepsin S (CTSS or EC 3.4.22.27)-Therapeutics Assessment 12
Assessment by Mechanism of Action 12
Assessment by Route of Administration 13
Assessment by Molecule Type 14
Cathepsin S (CTSS or EC 3.4.22.27)-Companies Involved in Therapeutics Development 16
Amura Holdings Ltd 16
F. Hoffmann-La Roche Ltd 16
Fusion Antibodies Ltd 16
Sanofi 17
Virobay Inc 17
Cathepsin S (CTSS or EC 3.4.22.27)-Drug Profiles 19
AM-3840-Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
AM-3876-Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
Fsn-0503h-Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
RG-7625-Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
RO-5461111-Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
SAR-114137-Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
VBY-129-Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
VBY-285-Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
VBY-50365-Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
VBY-825-Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Cathepsin S (CTSS or EC 3.4.22.27)-Dormant Products 29
Cathepsin S (CTSS or EC 3.4.22.27)-Discontinued Products 30
Cathepsin S (CTSS or EC 3.4.22.27)-Product Development Milestones 31
Featured News & Press Releases 31
Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease 31
Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting 31
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 13
Number of Products by Stage and Molecule Type, H2 2017 15
Pipeline by Amura Holdings Ltd, H2 2017 16
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 16
Pipeline by Fusion Antibodies Ltd, H2 2017 17
Pipeline by Sanofi, H2 2017 17
Pipeline by Virobay Inc, H2 2017 18
Dormant Projects, H2 2017 29
Discontinued Products, H2 2017 30

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 13
Number of Products by Molecule Types, H2 2017 14
Number of Products by Stage and Molecule Types, H2 2017 14

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *